Coly‑Mycin M Injection (Colistimethate Sodium)
Compared with: Blackmores Conceive Well Gold 28 Tablets + 28 Capsules

Coly‑Mycin M (Colistimethate Sodium for Injection) is a polypeptide antibiotic indicated for severe infections caused by susceptible Gram‑negative bacilli, including Pseudomonas aeruginosa. Administered IV or IM at 2.5–5 mg/kg/day (colistin base activity) in divided doses, it achieves bactericidal concentrations in serum and tissues, with a half‑life of approximately 2–3 hours
FDA Access Data

Colistimethate Sodium (equivalent to colistin base activity)

Each vial: 150 mg colistin base activity (as pentasodium colistimethate)
FDA Access Data
Other Popular and Common Names
Colistin Methanesulfonate

CMS for Injection

Polymyxin E Methanesulfonate

Coly‑Mycin M Parenteral

Colistimethate (CMS) is a prodrug converted in vivo to colistin, which binds to the lipopolysaccharide and phospholipid components of the bacterial outer membrane. This disrupts membrane integrity, increases permeability, and causes rapid leakage of intracellular contents, leading to bacterial cell death

Severe Infections due to susceptible Gram‑negative bacilli:

Pseudomonas aeruginosa

Klebsiella pneumoniae

Escherichia coli

Enterobacter aerogenes

Empiric Therapy in suspected multidrug‑resistant Gram‑negative sepsis.

Infections Not Recommended: Proteus spp., Neisseria spp.
FDA Access Data

Patient Group Dose (Colistin Base Activity) Frequency Notes
Adults & Children ≥1 year 2.5–5 mg/kg/day Divided into 2–4 doses IV infusion over 3–5 minutes per dose; lower end for moderate, higher for severe infection
Drugs.com
Renal Impairment See table below Adjust per creatinine clearance
Obese Patients Based on ideal body weight To prevent overdose

Renal Dosing Adjustments

CrCl (mL/min) Total Daily Dose Dosing Interval
≥80 2.5–5 mg/kg/day q6–12 h
50–79 2.5–3.8 mg/kg/day q12 h
30–49 2.5 mg/kg/day q24 h or divided q12 h
10–29 1.5 mg/kg q36 h

IV Administration: Slow injection over 3–5 minutes; can also dilute in ≥50 mL compatible fluid for extended infusion.

IM Administration: Deep gluteal injection if IV access unavailable.

Monitoring: Serum levels not routinely available—monitor renal function and clinical response.

Formulation: Sterile lyophilized powder for injection

Reconstitution: Add 10 mL sterile water for injection to 150 mg vial, swirl gently—do not shake.

Presentation: Single‑dose vials; no preservatives.

Legal Status: Prescription Only (Rx‑only)

Pregnancy Category: C – Use only if clearly needed; animal studies show risk at high doses.

Breastfeeding: Small excretion into milk; monitor infant for gastrointestinal upset.

Pediatric Use: Approved ≥1 year; weight‑based dosing.

Elderly: No specific adjustment; greater risk of nephrotoxicity.

Renal Impairment: Dose adjust per table; to minimize accumulation and toxicity.

Nephrotoxicity (elevated creatinine, BUN)
Medscape Reference

Neurotoxicity (dizziness, paresthesias)

Local reactions at injection site (pain, erythema)

Serious:

Acute tubular necrosis leading to renal failure

Neurotoxic manifestations: neuromuscular blockade, apnea at high plasma concentrations
Medscape Reference

Hypersensitivity: rash, urticaria, anaphylaxis (rare)

Nephrotoxicity: Avoid concomitant nephrotoxins (aminoglycosides, vancomycin, amphotericin B); monitor renal function daily.

Neurotoxicity: Use with caution in patients with neuromuscular disorders (e.g., myasthenia gravis).

Overdosage: Signs include limb weakness, apnea—provide supportive care and consider extended dialysis.

Resistance Development: Restrict use to proven or strongly suspected infections; de-escalate when culture data available.

Therapeutic Class: Antibiotic, Ectopic Group

Pharmacologic Class: Polymyxin (Lipopeptide) Antibiotic

Legal Category: Prescription Only

Concomitant Agent Effect Recommendation
Aminoglycosides (e.g., gentamicin) Additive nephrotoxicity, neurotoxicity Avoid combination if possible; monitor closely
Vancomycin ↑Nephrotoxicity Monitor renal function
Neuromuscular Blockers Potentiation of blockade Use caution; monitor respiratory status
Amphotericin B ↑Kidney injury Avoid or monitor renal function
Radiographic Contrast Agents ↑Risk of acute kidney injury Ensure adequate hydration

FAQs – Coly‑Mycin M Injection
Q1. How soon does Coly‑Mycin M work?
A: Bactericidal effect begins within hours; clinical improvement typically observed within 48–72 hours of initiation.

Q2. Can Coly‑Mycin M treat Pseudomonas aeruginosa?
A: Yes—it is particularly indicated for serious P. aeruginosa infections resistant to other agents
FDA Access Data

Q3. Whatmonitoring is required?
A: Daily serum creatinine and BUN; neurological exam for signs of neurotoxicity.

Q4. How do I manage a missed dose?
A: Administer as soon as possible and resume schedule; do not double doses.

Q5. Is dose adjustment needed in kidney disease?
A: Yes—adjust per creatinine clearance per dosing table above

Q6. Can Coly‑Mycin M be used IM?
A: Yes—deep IM injection is an alternative when IV access is not feasible.

Q7. How should vials be stored?
A: Store powder at controlled room temperature (20–25 °C); protect from moisture.

Coly‑Mycin M, Colistimethate Sodium, Polymyxin Antibiotic, MDR Pseudomonas Treatment, Nephrotoxic Antibiotic, EZ Chemist, Colistin IV Injection, Gram‑Negative Sepsis Therapy, Coly‑Mycin M Dosage, Colistin Base Activity Guide